Open AccessMulti-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients
Author(s) -
Jaap Jan Zwaginga,
Bronno van der Holt,
Peter A. te Boekhorst,
Bart J. Biemond,
MarkDavid Levin,
René van der Griend,
Anneke Brand,
Sonja Zweegman,
Hans Pruijt,
V. M. J. Novotný,
Art Vreugdenhil,
Marco R. de Groot,
Okke de Weerdt,
E.C.M. van Pampus,
Tanja M. van Maanen-Lamme,
Shulamiet Wittebol,
Martin R. Schipperus,
M. H. Silbermann,
Peter C. Huijgens,
Marleen Luten,
Rene Hollestein,
Jan Brakenhoff,
J. G. Schrama,
F.A.A. Valster,
Gerjo A. Velders,
Harry R. Koene
Publication year - 2014
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2014.110213
Subject(s) - rituximab , dosing , medicine , immune thrombocytopenia , open label , randomized controlled trial , single center , oncology , platelet , lymphoma